The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•30 March 2026•

1 min read

VolitionRx Shares Supported by Positive Mayo Clinic Study on Nu.Q Biomarkers

Key Facts

1A peer-reviewed clinical study published in Shock journal shows elevated nucleosome levels in trauma patients.

2Nu.Q®H3.1 and Nu.Q®H3R8 tests showed even higher levels in patients who experienced complications from trauma.

Version History

1 additional source confirmed this story

VolitionRx Limited announced the publication of a peer-reviewed clinical study in the journal Shock, conducted in collaboration with the prestigious Mayo Clinic. The study demonstrates that the company's Nu.Q epigenetic biomarkers are significantly elevated in patients suffering from physical trauma. Specifically, the Nu.Q®H3.1 and Nu.Q®H3R8 tests showed even higher levels in patients who experienced severe complications following their injuries. This clinical validation from a world-renowned institution like the Mayo Clinic enhances the credibility of Volition's diagnostic platform. The findings suggest that these biomarkers could play a crucial role in identifying and monitoring trauma severity in acute care settings. Investors view this as a positive catalyst for VNRX, as it supports the company's ongoing efforts to commercialize its innovative diagnostic technology.